Serum concentration of lipoprotein(a) decreases on treatment with hydrosoluble coenzyme Q10 in patients with coronary artery disease: Discovery of a new role

International Journal of Cardiology

Volumn 68, Issue 1, 1999, Pages 23-29

  Singh, Ram B ^a   Niaz, Mohammad A ^a  

^a Medical Hospital and Research Centre Moradabad   (India)

Author keywords

Blood glucose; Cholesterol; Coenzyme Q10; Coronary artery disease; Free radical stress; HDL; LDL; Lipoprotein(a); Oxidative stress; Q Gel

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; Q GEL; UBIDECARENONE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; HUMAN; HYPERLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSTABLE ANGINA PECTORIS;

ANALYSIS OF VARIANCE; ANTIOXIDANTS; BLOOD GLUCOSE; CHOLESTEROL; CORONARY DISEASE; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; OXIDATIVE STRESS; PLACEBOS; UBIQUINONE;

EID: 0032962630     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(98)00323-4     Document Type: Article

References (32)

1. Orthgomor K., Mittleman M.A., Schenckgustafsson K.et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation. 95:1997;329-334.
2. Fortmann S.P., Marcovina S.M. Lipoprotein(a), a clinically elusive lipoprotein particle. Circulation. 95:1997;295-296.
3. Wild S.H., Fortmann S.P., Marcovina S.M. A prospective case control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five City Project participants. Arterioscler Thromb. 17:1997;239-245.
4. Rosenson R.S. Beyond low density lipoprotein cholesterol: a prospective on low high density lipoprotein disorders and Lp (a) lipoprotein excess. Arch Intern Med. 156:1996;1278-1284.
5. Schaefer E.J., Lamon-Favo S., Jenner J.L., McNamara J.R., Ordovas J.M., David C.E. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Primary Prevention Trial. J Am Med Assoc. 271:1994;999-1003.
6. Editorial. Lipoprotein(a). Lancet, 1991;331:397-8.
7. Shaukat N., Douglas J.T., Bennett J.L., De Bono D.P. Can physical activity explain the differences in insulin levels and fibronolytic activity between young Indo-origin and European relatives of patients with coronary artery disease. Fibrinolysis. 9:1995;1-9.
8. Sandholzer C., Halman D.M., Saha N., Sigurdsson G., Gsaszar A. Effect of apoliproprotein(a) polymorphism on the lipoprotein(a) concentration in seven ethnic groups. Hum Genet. 86:1991;607-614.
9. Singh RB, Goel VK, Niaz MA. Lipoprotein(a) and Coronary risk factors in urban population and their siblings in rural area. J Am Coll Nutr 1999 (in press).
10. Bhatanagar D., Anand I.S., Durrington P.N.et al. Coronary risk factors in people from the Indian subcontinent living in West London and their siblings in India. Lancet. 345:1995;405-409.
11. Budde T., Fechtrup C., Bosenberg E. Plasma lipoprotein(a) levels correlate with the number, severity and length extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb. 14:1994;1730-1736.
12. Wang X.L., Tarn C., McCredie R.M., Wilken D.E.L. Determinants of severity of coronary artery disease in Australian men and women. Circulation. 89:1994;1974-1981.
13. Gupta R., Gupta V.P. Metaanalysis of coronary heart disease prevalence in India. Indian Heart J. 48:1996;241-245.
14. Balarajan R. Ethnic differences in mortality from ischemic heart disease and cerebrovascular disease in England and Wales. Br Med J. 302:1991;560-564.
15. Hughes K. Trends in mortality from ischemic heart disease in Singapore. Inter J Epidemiol. 15:1996;44-50.
16. Cremer P., Nagel D., Labrot B. Lipoprotein(a) as predictor of myocardial infarction in comparison to fibronigen, LDL cholesterol, and other risk factors: results from the prospective Gottingen Risk incidence and Prevalence Study (GRIP). Eur J Clin Invest. 24:1994;444-453.
17. Johansson J., Egberg N., Asplund Carlson A., Carlson I.A. Nicotinic acid treatment shifts, the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men. J Cardiovasc Risk. 4:1997;165-172.
18. Postiglion A., Panico S., Lewis B.et al. New and candidate risk factors for coronary heart disease. Nutr Meta Cardiovasc Dis. 4:1994;233-256.
19. Singh RB, Wander GS, Rastogi A, et al. Randomized double blind, placebo controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovas Drug Ther 1998 (in press).
20. Stocker R., Bowry W.V., Frei B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alphatocopherol. Proc Natl Acad Sci, USA. 88:1991;1646-1650.
21. Wahlquist M.L., Wattanapenparboon N., Sarige G.S., Kannar D. Bioavailability of two different formulations of coenzyme Q10 in healthy subjects. Asia Pac J Clin Nutr. 7:1998;37-40.
22. Chopra R.K., Goldman R., Sinatra S.T., Bhagavan H.N. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int J Vit Nutr Res. 68:1998;109-113.
23. Serebuany V.L., Ordonez J.V., Herzog W.R.et al. Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CDSI/CD 61) recepter expression. J Cardiovasc Pharmacol. 29:1997;16-22.
24. Esterbauer H., Cheeseman K.H. Determination of aldehyde peroxidation products malondialdehyde and 4 hydroxynonenal. Method Enzymol. 186:1990;407-421.
25. Niato C., Kawamure M., Yamamoto Y. Lipid peroxides as the initiating factor of atherosclerosis. Am NY Acad Sci. 676:1993;27-45.
26. Lunec J., Hallovan S.P., White A.G., Dormandy T.L. Free radical oxidation (peroxidation) products in serum and synovial fluids in rheumatoid arthritis. J Rheumatol. 8:1981;233-245.
27. Sandkamp M., Funke H., Schelte H., Kohlor E., Assmann G. Lipoprotein(a) and the risk factor of myocardial infarction at a young age. Clin Chem. 36:1990;20-23.
28. Kostner G.M., Avogaro P., Cazzolato G., Marth E., Bittolo-Bon G., Qulnle G.B. Lipoprotein(a) and the risk for myocardial infarction. Atherosclerosis. 38:1961;51-61.
29. Naylor WG. The use of coenzyme Q10 to protect ischaemic heart muscle. In: Yamamura Y, Folkers K, Ito Y, editors. Biomedical aspects of Coenzyme Q Vol 2. Amsterdam: Elsevier, 1980:409-24.
30. Takasawa K, Fuse K, Konishi T, Watanabe Y. Prevention of premature ventricular contractions with coenzyme Q10 after coronary artery bypass grafting. In: Folkers K, Littarru GP, Yamagami T, editors. Biomedical and Clinical Aspects of Coenzyme Q. Vol 6. Amsterdam: Elsevier, 1991:357-9.
31. Atar D., Mortensen S.A., Flachs H., Herzog W.R. Coenzyme Q10 protects ischaemic myocardium in an open chest Swine model. Clin Invest. 71:1993;103-111.
32. Bruckert E., Devidolf P., Grimaldi A.et al. Increased serum levels of lipoprotein(a) in diabetes millitus and their reduction with glycemic control. J Am Med Assoc. 263:1990;35-36.